Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
Synonyms: Heerfordt syndrome (USA form), Heerfordt's disease, Heerfordt-Mylius syndrome, Heerfordt-Waldenstrom syndrome, Waldenstrom's uveoparotitis, uveoparotid fever, febris uveoparotidae, neuro-uveoparotitis syndrome, uveoparotitic paralysis, uveomeningitic syndrome
See also the separate Sarcoidosis article.
- Swelling of parotid ± other salivary/lacrimal glands.
Several physicians were involved in its discovery and characterisation.Hence, it has a plethora of eponymous names. It forms a small proportion (<5%) of sarcoidosis cases, with variation in its incidence across different ethnic groups.
Involvement of the eyes, nervous system and salivary glands in isolation occurs frequently in sarcoidosis. Strictly, to fit the criteria of this syndrome, they must all present in combination, along with episodes of fever.
Other features of sarcoidosis may co-exist with the syndrome, such as skin lesions and evidence of thoracic involvement. It represents a form of neurosarcoidosis, so there may be other neurological involvement such as meningism, or other cranial nerve lesions leading to ophthalmoplegia, pupillary reflex dysfunction or other abnormalities.
- Young adulthood - more frequent in those aged between 20-40 years.
- More common presentation in women than in men.
Additional features of sarcoidosis may appear alongside the core syndrome.
Fever and constitutional upset
- The patient may have experienced paroxysmal episodes of fever or night sweats.
- Other symptoms such as headache and weight loss may occur.
- Acute uveitis presents with:
- Eye discomfort
- Blurred vision
- Seeing 'floaters'
- Red eye
- The lacrimal glands may be involved, causing puffy eyelids.
- May be unilateral or bilateral - bilateral in 73% of cases of parotid sarcoidosis.
- Diffuse, painless swelling of the parotid ± other salivary glands/lacrimal glands.
- May cause a dry mouth.
Cranial nerve palsy
- Strictly speaking, it must affect the facial nerve (CN VII).
- There is abrupt onset within a short period of the parotid swelling.
- The nerve is thought to be entrapped/infiltrated by granulomatous inflammation in the parotid gland or facial canal but the exact site remains uncertain.
- There may be accompanying disturbance of taste (chorda tympani dysfunction - supporting presumed site of lesion).
- Other cranial nerves can be involved. Symptoms of other cranial neuropathies commonly involved in neurosarcoidosis include:
- Disturbance of smell.
- Blurred vision/diplopia/sight impairment.
- Speech or swallowing difficulty.
- Weakness of trapezius/neck muscles.
- Tongue deviation or atrophy.
These may include:
- Evidence of recent weight loss.
- Facial swelling around the cheeks.
- Swollen eyelids.
- Inflamed eyes, squinting in light.
- Visible facial nerve palsy with drooping of features on one side (NB: if bilateral, facial symmetry may be preserved).
Cranial nerve palsy
- Lower motor neurone CN VII lesion - affects the whole face including the forehead and eyelids.
- Bell's phenomenon may be seen - upward, outward turning of the eyeball as the patient attempts to close the eyelids.
- Examine other cranial nerves. as other palsies may be present.
- If an alternative cranial nerve palsy is found in place of facial nerve paralysis, most would still define the syndrome as Heerfordt's, provided all other classical features of the syndrome are present.
- Bilateral lower motor neurone facial nerve palsy of abrupt onset in young adults is virtually always due to sarcoidosis.
- There may be accompanying signs of meningism.
- Anterior uveitis is painful and presents with:
- Pupillary irregularity.
- Injected conjunctivae next to the cornea (so-called perilimbal flush).
- Fundoscopy may show retinal detachment or vasculitis and papilloedema if there is posterior uveitis.
- Severe cases may show hypopyon - a collection of yellowish inflammatory exudate and cells at the bottom of the anterior chamber.
- Slit-lamp examination may reveal cells, flare and precipitates in the anterior chamber/vitreous humour.
- Diffuse, firm swelling which is not tender to palpation.
Thoroughly examine the heart, chest, skin, eyes, joints, abdomen, lymph fields, nervous system, salivary glands and upper respiratory tract in all patients presenting with suspected sarcoidosis in order to detect the full extent of the disease.
The syndrome is a fairly distinct clinical entity and once recognised is not likely to be confused with illnesses other than sarcoidosis, being virtually pathognomonic for the disease.
For more information about other causes of parotid enlargement, see the separate Salivary Gland Disorders article.
- Serum angiotensin-converting enzyme (ACE) - which is usually elevated.
- Hypercalciuria occurs in about 30% of patients and hypercalcaemia in about 10%.
- Gallium scanning of the parotid gland may be helpful.
- Biopsy of the parotid gland and other sites of the disease may be required in some cases and may reveal the classic non-caseating epithelioid granulomata.
- Optic nerve involvement may be detected by imaging - MRI is of more assistance than CT in this situation.
Additional investigations may include:
- CXR - to look for evidence of hilar adenopathy or pulmonary involvement.
- Basic screening bloods such as ESR, FBC, U&E/LFTs, which are usually performed as baseline investigations but are fairly nonspecific.
- Autoantibodies if there is any suspicion of a connective tissue disease.
- Lumbar puncture, which may be needed where there is suspicion of meningitis - in sarcoidosis, it shows a sterile pleomorphic inflammatory picture.
Sarcoidosis tends to undergo spontaneous remission in 50-60% of cases and does not always require active management. The disease course is very variable and difficult to predict.
- The most troublesome aspect of the syndrome to manage is uveitis which may be sight-threatening and requires expert ophthalmological assessment and monitoring. Topical or systemic corticosteroids are the mainstays of management of ocular sarcoidosis. Other immunomodulatory drugs may be used as steroid-sparing or disease-modifying agents.
- Systemic steroids are used to treat the facial nerve palsy if it is troublesome enough and does not resolve - usually successfully.
Surgical intervention may be used to treat the complications of cataracts or vitreous opacification, once active disease has been controlled. Uveitis increases the risk of glaucoma, so a significant proportion of patients may require trabeculectomy or other glaucoma drainage devices.
- Ocular sicca syndrome.
- Band keratopathy.
- Vitreous haemorrhage.
- Retinal detachment.
- Cystoid macular oedema.
- Sight impairment due to macular disease.
- Optic atrophy.
- Spinal cord lesions causing motor/sensory paresis.
- Pituitary dysfunction.
- Sterile meningitis.
- Oral infections/dental caries due to reduced saliva secretion.
Prognosis is very variable:
- Of the acute presentations of sarcoidosis, it carries a relatively poorer outlook in terms of severity of disease; however, permanent complications can be avoided or ameliorated by adequate management in many cases.
- Facial paralysis tends to recover or respond to steroids.
- Heerfordt's syndrome is not thought to relapse once it has remitted or responded to therapy; however, other patterns of sarcoidosis may follow it.
- The degree of involvement of sarcoidosis at other sites will influence the overall prognosis.
- One American study reported that of all deaths reported in the period 1988-2007, 0.05% listed sarcoidosis as the primary cause on the death certificate.
The cause of sarcoidosis is not really understood so primary preventative strategies do not exist. Patients with sarcoidosis are prone to relapse and may benefit from long-term specialist follow-up. Patients should be advised to seek early help if they experience symptoms potentially attributable to sarcoidosis.
Did you find this information useful?
Further reading & references
- SILA; The Sarcoidosis Charity
- Cakmak SK, Gonul M, Gul U, et al; Sarcoidosis involving the lacrimal, submandibular, and parotid glands with panda sign. Dermatol Online J. 2009 Mar 15 15(3):8.
- Dua A, Manadan A; Images in clinical medicine. Heerfordt's syndrome, or uveoparotid fever. N Engl J Med. 2013 Aug 1 369(5):458. doi: 10.1056/NEJMicm1303454.
- Chappity P, Kumar R, Sahoo AK; Heerfordt's Syndrome Presenting with Recurrent Facial Nerve Palsy: Case report and 10-year literature review. Sultan Qaboos Univ Med J. 2015 Feb 15(1):e124-8. Epub 2015 Jan 21.
- Heerfordt's disease or syndrome; whonamedit.com
- Darlington P, Tallstedt L, Padyukov L, et al; HLA-DRB1* alleles and symptoms associated with Heerfordt's syndrome in sarcoidosis. Eur Respir J. 2011 Nov 38(5):1151-7. Epub 2011 May 12.
- Longo N, Ghaderi M; Primary parotid gland sarcoidosis: case report and discussion of diagnosis and treatment. Ear Nose Throat J. 2010 Apr 89(4):E6-10.
- Funk M, Santana O; An unusual presentation of an uncommon disease. Int J Gen Med. 2009 Dec 29 2:259-61.
- James DG, Sharma OP; Parotid gland sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2000 Mar 17(1):27-32.
- Petropoulos IK, Zuber JP, Guex-Crosier Y; Heerfordt syndrome with unilateral facial nerve palsy: a rare presentation of sarcoidosis. Klin Monbl Augenheilkd. 2008 May 225(5):453-6.
- Fujiwara K, Furuta Y, Fukuda S; Two Cases of Heerfordt's Syndrome: A Rare Manifestation of Sarcoidosis. Case Rep Otolaryngol. 2016 2016:3642735. doi: 10.1155/2016/3642735. Epub 2016 Jan 17.
- Swigris JJ, Olson AL, Huie TJ, et al; Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011 Jun 1 183(11):1524-30. Epub 2011 Feb 17.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.